Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

• ClinicalTrials.gov Identifier: NCT04120402
• Recruitment Status: Completed
• First Posted: October 9, 2019
• Last Update Posted: June 8, 2023
• Sponsor: Eupraxia Pharmaceuticals Inc.
• Collaborator: NBCD A/S
• Information provided by (Responsible Party): Eupraxia Pharmaceuticals Inc.

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of EP-104IAR in patients with osteoarthritis (OA) of the knee

Condition or disease	Intervention/treatment	Phase
Osteoarthritis, Knee	Drug: EP-104IAR 25 mg; Drug: Vehicle	Phase 2

Detailed Description:

This is a randomized, double-blind, placebo-controlled, single injection, 24-week study to evaluate the safety, efficacy and PK of EP-104IAR in subjects with osteoarthritis knee pain

Following screening and baseline assessments to determine eligibility, each participant will receive a single IA injection of either EP-104IAR or placebo (vehicle). Participants will be followed up for 24 weeks following the injection for safety, PK and efficacy assessments.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 318 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Subjects will be randomized to received either EP-104IAR or placebo (vehicle) in a parallel group fashion.
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 2, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety, Efficacy and Pharmacokinetics of Single Dose EP-104IAR for 24 Weeks in Patients With Osteoarthritis of the Knee
• Actual Study Start Date: September 10, 2021
• Actual Primary Completion Date: May 17, 2023
• Actual Study Completion Date: June 1, 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: EP-104IAR 25 mg; A single use intra-articular injection containing 25 mg of EP-104IAR	Drug: EP-104IAR 25 mg; Single 5 mL intra-articular injection
Placebo Comparator: Placebo (vehicle); A single use intra-articular injection containing no active ingredients	Drug: Vehicle; Single 5 mL intra-articular injection

Outcome Measures

Primary Outcome Measures :

1. Difference in change from baseline between EP-104IAR and vehicle in WOMAC Pain subscale [ Time Frame: 12 weeks ]
   WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. Pain subscale includes 5 questions related to the pain of osteoarthritis (score range 0-20).

Secondary Outcome Measures :

1. Difference in change from baseline between EP-104IAR and vehicle in WOMAC Function subscale [ Time Frame: 12 weeks ]
   WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. Function subscale includes 17 questions related to the physical functioning of osteoarthritis e.g. stair use, standing, walking etc. (score range 0-68)
2. Difference between EP-104IAR and vehicle in the area under the curve (AUC) of WOMAC Pain subscale [ Time Frame: 12 weeks ]
   WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. Pain subscale includes 5 questions related to the pain of osteoarthritis (score range 0-20).
3. Difference in change from baseline between EP-104IAR and vehicle in WOMAC Pain subscale [ Time Frame: 24 weeks ]
   WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index. Pain subscale includes 5 questions related to the pain of osteoarthritis (score range 0-20).
4. Difference between EP-104IAR and vehicle in OMERACT-OARSI strict responders [ Time Frame: 12 weeks ]
   OMERACT-OARSI = Outcome Measures in Rheumatology-Osteoarthritis Research Society International

Eligibility Criteria

• Ages Eligible for Study: 40 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

• Males or females, aged ≥40 years
• Body Mass Index (BMI) ≤ 40.0 kg/m2
• Diagnosis of primary OA of the Index knee, with symptoms present for at least 6 months
• OA severity Grade 2 or 3 (based on Kellgren Lawrence Grading Scale)
• Unsatisfactory pain relief from at least 2 prior standard OA treatments
• Qualifying pain in the Index knee during the baseline period
• Ambulatory (without the need for a cane/other walking aide)
• Female subjects willing to use highly effective birth control methods to prevent pregnancy
• Willing and able to comply with study procedures and restrictions, including abstaining from use of restricted medications.

Key Exclusion Criteria:

• OA of the Index knee due to acute injury or trauma, or unstable joint
• X-ray evidence of chondrocalcinosis
• Diagnosed or suspected ipsilateral hip OA
• Knee pain that is not attributable to OA of the knee
• Any other disorders that impact mobility, strength or sensation, or are a co-existent source of pain or inflammation that interfere with assessment of knee pain and function
• History of infection in the Index knee
• Skin breakdown on the Index knee where the injection will take place
• Total Knee Replacement, or any other surgery (including arthroscopy) for the Index knee within prior 12 months, or planned surgery during the study
• Total Knee Replacement Surgery of the non-Index knee within prior 6 months, or planned surgery (any location) during the study that would require a restricted medication
• IA injection of corticosteroids in any joint within prior 3 months or IA injection of extended-release corticosteroids in any joint within prior 6 months
• IA injection in the Index knee of platelet rich plasma, or other prolotherapy within prior 3 months, or hyaluronic acid within prior 6 months
• Recent, current or planned use of corticosteroids for any indication (except for permitted uses)
• Recent, current or planned use of prohibited medications (including analgesics, marijuana, investigational drugs and devices, immunosuppressive therapy), or unwilling or unable to stop using prohibited medications during the study.
• Conditions including: sarcoidosis, amyloidosis, osteomyelitis, Cushing's Syndrome, hepatic or renal disease, Psychotic disorder, bipolar disorder, symptomatic depressive or anxiety disorders.
• Current malignancy of any type, or history of a malignancy within prior 12 months
• Active or quiescent systemic fungal, bacterial (including tuberculosis) viral (including HIV, Hepatitis B or C) or parasitic infections, or ocular herpes simplex, or any recent infection requiring IV or oral antibiotics
• Laboratory results indicative of adrenal insufficiency, diabetes or renal or hepatic disease.
• Positive urine drug screen for a substance of abuse
• Females who are pregnant, lactating
• Known or suspected hypersensitivity or contraindication to ingredients in the study drug

Contacts and Locations

Locations

Czechia

CCR Brno, s.r.o

Brno, Czechia

CCR Czech a.s

Pardubice, Czechia

CCR Prague, s.r.o

Prague, Czechia

Denmark

The Parker Institute, Frederiksberg Hospital

Frederiksberg, Denmark

Sanos Clinic Nordjylland

Gandrup, Denmark

Sanos Clinic Herlev

Herlev, Denmark

Sanos Clinic Syddanmark

Vejle, Denmark

Poland

NZOZ BIF-MED s.c

Bytom, Poland

Medyczne Centrum Hetmańska

Poznań, Poland

Somed CR

Warsaw, Poland

Somed CR

Łódź, Poland

DC-MED

Świdnica, Poland

Sponsors and Collaborators

Eupraxia Pharmaceuticals Inc.

NBCD A/S

Investigators

• Study Director: Amanda Malone; Eupraxia Pharmaceuticals

More Information

• Responsible Party: Eupraxia Pharmaceuticals Inc.
• ClinicalTrials.gov Identifier: NCT04120402
• Other Study ID Numbers: EP-104IAR-201
• First Posted: October 9, 2019
• Last Update Posted: June 8, 2023
• Last Verified: June 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Osteoarthritis; Osteoarthritis, Knee; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases